Hiring, not reorganization, is the answer to rare disease expertise issues at the US Food and Drug Administration’s Center for Drug Evaluation and Research, Director Patrizia Cavazzoni said.
Advocates and stakeholders have argued for years that the FDA could better handle rare disease applications and drug development with...







